Novartis acquires Admune Therapeutics and licenses agreements with Xoma and Palobiofarma to expand its immuno-oncology portfolio.
Novartis is set to invest an additional $15 million dollars in Gamida Cell for development of stem cell therapies.
Pharmaceuticals company rolls out the Novartis Access program that supplies low-income countries with essential drugs for diabetes, cardiovascular diseases and breast cancer.
The US Food and Drug Administration has approved the extended use of Promacta for children ages one year and up who are suffering from idiopathic thrombocytopenic purpura (ITP).
The US Food and Drug Administration has discovered that Norvatis drug Gilenya can be directly linked to progressive multifocal leukoencephalopathy which can lead to serious brain damage.
A heart failure drug, manufactured by international pharmaceutical company Novartis, has been approved by the US Food and Drug Administration (FDA) on Tuesday.
